Portfolio — 23 March 2026

The Assistant Minister for Productivity, Competition, Charities and Treasury, Dr Andrew Leigh, spoke in support of the Treasury Laws Amendment (Genetic Testing Protections in Life Insurance) Bill on second reading, making the case that prohibiting life insurers from using genetic test results in underwriting decisions will eliminate a structural barrier to Australians getting tested and participating in medical research [TA-260323-house-068fade26cde:s080].

The Minister anchored the equity argument in concrete evidence: approximately 10 per cent of individuals who disclosed genetic test results to insurers received less favourable terms or were denied cover outright — a deterrent effect that has suppressed both personal health decisions and research participation [TA-260323-house-068fade26cde:s080]. He pointed to the United Kingdom's experience as precedent, noting that country implemented an equivalent ban in 2001.

The bill's legislative design balances the prohibition with operational continuity for the industry. Insurers retain the ability to assess risk using symptoms, diagnoses, and family history — the traditional actuarial toolkit — while individuals who hold test results that work in their favour retain the option to voluntarily disclose them [TA-260323-house-068fade26cde:s080].

The mechanism aligns the Insurance Contracts Act with the Disability Discrimination Act, closing a legislative gap that had allowed practices under one statute that the other was designed to prevent.

The Minister framed the policy in equity terms: life insurance secures families' financial futures, and Australians carrying genetic risk should not face a binary choice between protecting their health knowledge and protecting their financial security. The downstream benefit — reduced fear of genetic testing driving higher research participation — adds a public health dimension to what is primarily a financial services reform.

No prior context candidates were available for this Note period. The observations flagged by Stage 1 — covering specific conditions such as BRCA1/BRCA2 variants and Huntington's disease, ethnic disparities in genetic discrimination, and the Insurance Contracts Act/Disability Discrimination Act alignment — are not directly sourced in the parliamentary record supplied and are not carried into this summary.